EA014820B1 - Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности - Google Patents
Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности Download PDFInfo
- Publication number
- EA014820B1 EA014820B1 EA200802104A EA200802104A EA014820B1 EA 014820 B1 EA014820 B1 EA 014820B1 EA 200802104 A EA200802104 A EA 200802104A EA 200802104 A EA200802104 A EA 200802104A EA 014820 B1 EA014820 B1 EA 014820B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- opioid receptor
- receptor antagonist
- dissociative
- personality
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract description 18
- 229960001736 buprenorphine Drugs 0.000 title abstract description 18
- 102000048260 kappa Opioid Receptors Human genes 0.000 title abstract description 5
- 108020001588 κ-opioid receptors Proteins 0.000 title abstract description 5
- 208000018459 dissociative disease Diseases 0.000 title description 14
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000005557 antagonist Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 150000002170 ethers Chemical class 0.000 claims description 7
- 239000002618 kappa opiate receptor antagonist Substances 0.000 claims description 7
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 7
- 229960004127 naloxone Drugs 0.000 claims description 7
- 239000003401 opiate antagonist Substances 0.000 claims description 6
- 108090000137 Opioid Receptors Proteins 0.000 claims description 4
- 102000003840 Opioid Receptors Human genes 0.000 claims description 4
- 230000008520 organization Effects 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 abstract description 26
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 12
- 230000002035 prolonged effect Effects 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000030990 Impulse-control disease Diseases 0.000 description 5
- 206010034719 Personality change Diseases 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000012839 conversion disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010002942 Apathy Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000001836 Firesetting Behavior Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 208000035713 Dissociative fugue Diseases 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006389 acute stress response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 206010023461 kleptomania Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- -1 macrogel 6000 Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 108010081490 naloxone receptor Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000021400 peanut butter Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200802104A1 EA200802104A1 (ru) | 2009-04-28 |
| EA014820B1 true EA014820B1 (ru) | 2011-02-28 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200802104A EA014820B1 (ru) | 2006-04-04 | 2007-04-03 | Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (OSRAM) |
| EP (1) | EP2001456B1 (OSRAM) |
| JP (1) | JP5128578B2 (OSRAM) |
| AT (1) | ATE450256T1 (OSRAM) |
| AU (1) | AU2007236003B2 (OSRAM) |
| CA (1) | CA2646899C (OSRAM) |
| CY (1) | CY1109862T1 (OSRAM) |
| DE (1) | DE502007002185D1 (OSRAM) |
| DK (1) | DK2001456T3 (OSRAM) |
| EA (1) | EA014820B1 (OSRAM) |
| ES (1) | ES2337622T3 (OSRAM) |
| HR (1) | HRP20100113T1 (OSRAM) |
| PL (1) | PL2001456T3 (OSRAM) |
| PT (1) | PT2001456E (OSRAM) |
| RS (1) | RS51211B (OSRAM) |
| SI (1) | SI2001456T1 (OSRAM) |
| WO (1) | WO2007115975A2 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2679661C1 (ru) * | 2013-12-20 | 2019-02-12 | Х. Лундбекк А/С | Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101925576B (zh) | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| PT3137081T (pt) | 2014-04-28 | 2018-02-08 | Orphomed Inc | Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| EP4489730A1 (en) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451009A2 (en) * | 1990-03-22 | 1991-10-09 | Glover Hillel | Pharmaceutical composition comprising opiate antagonists for the treatment of emotional numbness |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| WO2002049643A1 (en) * | 2000-12-21 | 2002-06-27 | The Mclean Hospital Corporation | Treatment of depression |
| WO2003080022A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Analgesics for nasal administration |
| WO2005084654A2 (en) * | 2004-03-02 | 2005-09-15 | Pharmacia Corporation | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
| WO2005117838A1 (en) * | 2004-06-02 | 2005-12-15 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1613617A4 (en) * | 2003-04-04 | 2009-02-18 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS |
| ME01072B (me) * | 2004-05-26 | 2012-10-20 | Inotek Pharmaceuticals Corp | Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu |
-
2007
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451009A2 (en) * | 1990-03-22 | 1991-10-09 | Glover Hillel | Pharmaceutical composition comprising opiate antagonists for the treatment of emotional numbness |
| US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
| WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| WO2002049643A1 (en) * | 2000-12-21 | 2002-06-27 | The Mclean Hospital Corporation | Treatment of depression |
| WO2003080022A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Analgesics for nasal administration |
| WO2005084654A2 (en) * | 2004-03-02 | 2005-09-15 | Pharmacia Corporation | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
| WO2005117838A1 (en) * | 2004-06-02 | 2005-12-15 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and derivatives |
Non-Patent Citations (5)
| Title |
|---|
| MAGUE S.D. ET AL.: "Antidepressant-like effects of [kappa]-opioid receptor antagonists in the forced swim test in rats", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 01 APR. 2003 UNITED STATES, vol. 305, no. 1, 1 April 2003 (2003-04-01), pages 323-330, XP002437983, ISSN: 0022-3565, page 326, page 329 * |
| MAREMMANI I. ET AL.: "Buprenorphine as a psychoactive drug", ITALIAN JOURNAL OF PSYCHOPATHOLOGY 2006 ITALY, vol. 12, no. 3, 2006, pages 332-341, XP002437984, ISSN: 1592-1107, abstract * |
| METCALF M.D. ET AL.: "Kappa opioid antagonists: Past successes and future prospects", AAPS PHARMSCI 27 OCT. 2005 UNITED STATES, vol. 7, no. 3, 27 October 2005 (2005-10-27), page 28p, XP002437985, ISSN: 1522-1059, cited in the application, the whole document * |
| SIMEON D.: "DEPERSONALISATION DISORDER: A CONTEMPORARY OVERVIEW", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 18, no. 6, 2004, pages 343-354, XP009085195, ISSN: 1172-7047, page 351 * |
| VADIVELU N. ET AL.: "Buprenorphine pharmacology and clinical applications", SEMINARS IN ANESTHESIA, SAUNDERS, CO, NEW YORK, NY, US, vol. 23, no. 4, December 2004 (2004-12), pages 281-290, XP004727515, ISSN: 0277-0326, page 285 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2679661C1 (ru) * | 2013-12-20 | 2019-02-12 | Х. Лундбекк А/С | Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007236003B2 (en) | 2012-10-18 |
| CY1109862T1 (el) | 2014-09-10 |
| US8063059B2 (en) | 2011-11-22 |
| EA200802104A1 (ru) | 2009-04-28 |
| ES2337622T3 (es) | 2010-04-27 |
| PT2001456E (pt) | 2010-03-03 |
| DK2001456T3 (da) | 2010-04-12 |
| WO2007115975A3 (de) | 2008-02-14 |
| SI2001456T1 (sl) | 2010-04-30 |
| AU2007236003A1 (en) | 2007-10-18 |
| EP2001456A2 (de) | 2008-12-17 |
| WO2007115975A2 (de) | 2007-10-18 |
| CA2646899A1 (en) | 2007-10-18 |
| ATE450256T1 (de) | 2009-12-15 |
| CA2646899C (en) | 2014-05-06 |
| JP2009532434A (ja) | 2009-09-10 |
| PL2001456T3 (pl) | 2010-05-31 |
| HRP20100113T1 (hr) | 2010-04-30 |
| US20090181999A1 (en) | 2009-07-16 |
| EP2001456B1 (de) | 2009-12-02 |
| JP5128578B2 (ja) | 2013-01-23 |
| DE502007002185D1 (de) | 2010-01-14 |
| RS51211B (sr) | 2010-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA014820B1 (ru) | Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности | |
| JP2021098743A (ja) | 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 | |
| ES2370409T3 (es) | Forma de dosificación que contiene oxicodona y naloxona. | |
| KR20150096370A (ko) | 항불안제 조성물, 제형 및 사용방법 | |
| JP2008520544A (ja) | 癌関連疲労のための処置 | |
| KR20190029682A (ko) | 수면 장애의 치료 및 예방 | |
| JP7108041B2 (ja) | 睡眠障害の治療及び予防 | |
| EP1938814A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
| US20110244057A1 (en) | Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions | |
| CN103002893B (zh) | 神经障碍性疼痛的治疗药或预防药 | |
| JP2003513028A (ja) | 肺疾患を治療するための方法および組成物 | |
| Swart | Drug interactions with tuberculosis therapy | |
| TW202203930A (zh) | 睡眠時呼吸中止症候群治療用醫藥 | |
| JP2005314347A (ja) | 疼痛抑制剤 | |
| US7897645B2 (en) | Herpesvirus-derived therapeutic agent for pain | |
| JP2020517730A (ja) | 心的外傷後ストレス障害を治療するための方法 | |
| US10610507B2 (en) | Methods for the treatment of sialorrhea | |
| Mathamshetty | BARBITURATES TOXICITY AND OVERDOSE MANAGEMENT: ADVANCES IN CLINICAL TREATMENT | |
| WO2025151396A1 (en) | Use of aprepitant for relieving side effects associated with the administration of weight loss medications | |
| JP2007528891A (ja) | 複合鎮痛剤医薬組成物 | |
| KR20220019715A (ko) | 만성 기침의 치료를 위한 [((1r,2s,5r)-2-이소프로필-5-메틸-사이클로헥산카르보닐)-아미노]-아세트산 이소프로필 에스테르 | |
| HK1062402A1 (zh) | 使用脫氧駱駝蓬堿治療由精神治療藥物中毒引致的中樞神經系統症狀 | |
| HK1062402B (en) | Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops | |
| HK1150754A (en) | Dosage form containing oxycodone and naloxone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |